Pathophysiology of encapsulating peritoneal sclerosis: lessons from findings of the past three decades in Japan

Clin Exp Nephrol. 2023 Sep;27(9):717-727. doi: 10.1007/s10157-023-02360-y. Epub 2023 Jun 6.

Abstract

Encapsulating peritoneal sclerosis (EPS), a condition with a high mortality rate, is a serious complication of peritoneal dialysis (PD). In Japan, EPS became a central issue in the clinical setting during the mid-90s and the beginning of this century. However, following the introduction of biocompatible neutral PD solutions containing lower levels of glucose degradation products, the incidence and clinical severity of EPS has been greatly lessened. During the past three decades, the etiology of EPS has been elucidated by findings obtained by peritoneal biopsy, laparoscopy, and surgical intervention. Accumulating findings suggest the need for a paradigm change on the nature of EPS pathophysiology; notably, EPS appears not to reflect peritoneal sclerosis per se, but rather the formation of a neo-membrane as a biological reaction to peritoneal injury. This narrative review looks back on the history of EPS in Japan, and discusses EPS pathophysiology, the impact of neutral PD solution on peritoneal protection, and a future novel diagnostic approach, ultra-fine endoscope, for the identification of patients at high risk of EPS.

Keywords: Encapsulating peritoneal sclerosis; Laparoscopy; Neo-membrane; Neutral solution; Peritoneal biopsy; Peritoneal histology; Ultra-fine endoscope.

Publication types

  • Review

MeSH terms

  • Dialysis Solutions / adverse effects
  • Humans
  • Japan / epidemiology
  • Peritoneal Dialysis* / adverse effects
  • Peritoneal Fibrosis* / diagnosis
  • Peritoneal Fibrosis* / etiology
  • Peritoneum / pathology
  • Sclerosis / complications
  • Sclerosis / pathology

Substances

  • Dialysis Solutions